NBSE Projected Dividend Yield
NeuBase Therapeutics Inc ( NASDAQ : NBSE )NeuBase Therapeutics is a preclinical-stage biopharmaceutical company. Co. is developing a modular peptide-nucleic acid antisense oligo (PATrOL™) platform to address genetic diseases, with a single approach. Co.'s disclosed programs are: NT-0100 program, which is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the Huntington's disease deoxyribonucleic acid or ribonucleic acid (RNA); NT-0200, which is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the dystrophy type 1 disease RNA; and NT-0300, which is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. 20 YEAR PERFORMANCE RESULTS |
NBSE Dividend History Detail NBSE Dividend News NBSE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |